Developer docs
API playgroundTry for free, no card

Search company profiles

Institute of Molecular Biotechnology

Full company profile

uuid000do5b

Namestring
Institute of Molecular Biotechnology
Legal namestring
Institute of Molecular Biotechnology
Websiteurl
oeaw.ac.at
Company typeenum
Private
Founded yearint
2003
Descriptiontext

The Institute of Molecular Biotechnology (IMBA) is a Vienna-based non-profit biomedical research institute operating under the Österreichische Akademie der Wissenschaften (Austrian Academy of Sciences, ÖAW), Austria's national academy and largest non-university research institution. Founded in 2003 and headquartered in Vienna, Austria, IMBA conducts advanced molecular biology research with particular prominence in stem cell biology, organoid technology, and molecular genetics. The institute gained European recognition for its pioneering work on brain organoids — miniature lab-grown models of the human brain used to study neurodevelopmental conditions and test treatments.

IMBA operates as a government-affiliated non-profit entity with no public revenue disclosure. Research funding derives primarily from public sources including the Austrian Science Fund (FWF) and European Research Council (ERC) grants. The institute employs 101-250 staff and operates within the broader ÖAW network, which encompasses multiple research institutes across Austria, more than 6,000 academic members, and a publishing arm (ÖAW Press) that distributes scholarly works across humanities, social sciences, and natural sciences. ÖAW Press operates an e-commerce storefront with individual publication pricing ranging from €8 to €208, alongside select Open Access options, and maintains distribution partnerships with JSTOR, CrossRef, and ORCID for digital discoverability.

IMBA serves the European academic and biomedical research community, with no direct paying customers in the commercial sense. Its stakeholder base comprises the Austrian government, EU funding bodies, collaborating universities, and the broader scientific community. The institute participates in international scientific collaborations, academic conferences, and the ÖAW's knowledge transfer programs including spin-off support. Marketing and outreach occur through institutional channels including academic events, science communication multimedia (podcasts, YouTube), social media presence, and the parent organization's publishing infrastructure.

Short descriptiontext

IMBA is a Vienna-based non-profit molecular biotechnology research institute under the Austrian Academy of Sciences, specializing in stem cell biology, organoid technology, and molecular genetics, primarily funded by public grants including FWF and ERC.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersVienna, Austria
HQ citystring
Vienna
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular biology research, biomedical research institute, stem cell research, organoid technology, biotechnology research
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
Product category
Biomedical Research Services
Revenue model1 record
1Academic Publishing and Book Sales
TypeOne Time License
Description

The Austrian Academy of Sciences Press (Verlag der Österreichischen Akademie der Wissenschaften) generates revenue through the sale of academic books, journals, and publications across disciplines including classical studies, archaeology, history, linguistics, musicology, and natural sciences. Publications are sold via an e-commerce storefront with pricing ranging from approximately €8 to €208 per item.

verlag.oeaw.ac.at
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Others
Pricing details1 tier
1Academic book and journal sales
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Individual book and journal prices; select open access publications available at no charge.

verlag.oeaw.ac.at
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

IMBA is a non-profit molecular biology and biomedical research institute conducting advanced research in stem cell biology, organoid technology, molecular genetics, and 3D cell culture models, with particular prominence in brain organoid research. Its outputs include peer-reviewed scientific publications, trained researchers, and collaborative research with universities and research institutions across Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Vienna Yearbook of Population Research achieved Q1 ranking in Scimago Journal-Ranking for the first time in 13 years
Product and service2 records
1Molecular biology and biomedical research services
CategoryBiomedical Research
Description

Fundamental and applied research in molecular biology, stem cell biology, organoid technology, molecular genetics, and 3D cell culture models, delivered to academic collaborators, universities, and research institutions.

2Brain organoid research program
CategoryNeuroscience Research
Description

Research program producing lab-grown human brain organoid models used by collaborators and academic partners to study neurodevelopmental conditions and test potential treatments.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or Integration
Description

The ÖAW Press partners with JSTOR for the digital distribution and academic indexing of its publications, enabling broad discoverability and access for academic institutions worldwide.

Strategic tierCoreTypeTechnology or Integration
Description

ORCID integration is supported and recommended for all authors publishing with the ÖAW Press, enabling unique researcher identification and attribution across publications.

Strategic tierCoreTypeTechnology or Integration
Description

CrossRef DOI services are used for all ÖAW Press publications, ensuring reliable citation linking and metadata standards.

4Association of European University Presses (AEUP)
Strategic tierCoreTypeGTM or Marketing Partner
Description

The ÖAW Press is a member of AEUP, a network of European university presses that promotes scholarly publishing and shares best practices across institutions.

verlag.oeaw.ac.at
5Arbeitsgemeinschaft der Universitätsverlage
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The ÖAW Press participates in the Working Group of University Publishers (AG Universitätsverlage), coordinating with other German-speaking academic publishers on shared standards and practices.

verlag.oeaw.ac.at
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1European Molecular Biology Laboratory (EMBL)
TypeDirect peer
Description

Intergovernmental research organization with sites across Europe conducting molecular biology and life science research; directly comparable as a publicly funded, multi-site European molecular biology research institute at similar scale and mission.

TypeDirect peer
Description

German publicly funded research institute focused on molecular genetics, genomics, and developmental biology; closely comparable mission, funding model, and scientific scope to IMBA within the same DACH-region academic ecosystem.

TypeDirect peer
Description

Large UK biomedical research institute conducting discovery research in molecular biology, stem cells, and genetics; directly comparable as a non-university, publicly funded biomedical research institute with similar headcount range and translational scope.

TypeDirect peer
Description

UK-based genomic and molecular biology research institute; comparable in its focus on molecular genetics, cell biology, and large-scale research infrastructure funded primarily through philanthropic and public grants.

TypeDirect peer
Description

MIT-affiliated non-profit biomedical research institute with similar headcount and focus on molecular biology, stem cells, and genetics; comparable as a small-to-mid-size, mission-driven research institute with strong publishing output.

TypeDirect peer
Description

US non-profit biomedical and genomic research organization; comparable in its mission-driven molecular biology and genomics research, though at substantially larger scale and with deeper industry partnership models.

TypeBroad incumbent
Description

Historic French non-profit research foundation with broader scope spanning infectious disease, immunology, and molecular biology; comparable as a publicly chartered European research institution, though operating at larger scale and broader thematic range.

TypeRegional player
Description

German publicly funded life sciences research institute within the Helmholtz Association; comparable in its DACH-region public funding model and molecular/cellular biology research portfolio, though more focused on infectious disease.

TypeBroad incumbent
Description

Sweden's leading medical university with substantial molecular biology and stem cell research programs; comparable as a publicly funded European institution conducting advanced biomedical research, though operating as a university rather than a standalone research institute.

TypeDirect peer
Description

Vienna-based molecular medicine research institute also operating under the Austrian Academy of Sciences; the closest geographic and institutional peer, conducting molecular-level biomedical research with similar funding structures and ÖAW affiliation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Institute of Molecular Biotechnology

Biomedical Research Servicesoeaw.ac.at

IMBA is a Vienna-based non-profit molecular biotechnology research institute under the Austrian Academy of Sciences, specializing in stem cell biology, organoid technology, and molecular genetics, primarily funded by public grants including FWF and ERC.

What Institute of Molecular Biotechnology does

The Institute of Molecular Biotechnology (IMBA) is a Vienna-based non-profit biomedical research institute operating under the Österreichische Akademie der Wissenschaften (Austrian Academy of Sciences, ÖAW), Austria's national academy and largest non-university research institution. Founded in 2003 and headquartered in Vienna, Austria, IMBA conducts advanced molecular biology research with particular prominence in stem cell biology, organoid technology, and molecular genetics. The institute gained European recognition for its pioneering work on brain organoids — miniature lab-grown models of the human brain used to study neurodevelopmental conditions and test treatments.

IMBA operates as a government-affiliated non-profit entity with no public revenue disclosure. Research funding derives primarily from public sources including the Austrian Science Fund (FWF) and European Research Council (ERC) grants. The institute employs 101-250 staff and operates within the broader ÖAW network, which encompasses multiple research institutes across Austria, more than 6,000 academic members, and a publishing arm (ÖAW Press) that distributes scholarly works across humanities, social sciences, and natural sciences. ÖAW Press operates an e-commerce storefront with individual publication pricing ranging from €8 to €208, alongside select Open Access options, and maintains distribution partnerships with JSTOR, CrossRef, and ORCID for digital discoverability.

IMBA serves the European academic and biomedical research community, with no direct paying customers in the commercial sense. Its stakeholder base comprises the Austrian government, EU funding bodies, collaborating universities, and the broader scientific community. The institute participates in international scientific collaborations, academic conferences, and the ÖAW's knowledge transfer programs including spin-off support. Marketing and outreach occur through institutional channels including academic events, science communication multimedia (podcasts, YouTube), social media presence, and the parent organization's publishing infrastructure.

Institute of Molecular Biotechnology firmographics

Firmographics
Name
Institute of Molecular Biotechnology
Legal name
Institute of Molecular Biotechnology
Website
https://oeaw.ac.at
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
IMBA is a Vienna-based non-profit molecular biotechnology research institute under the Austrian Academy of Sciences, specializing in stem cell biology, organoid technology, and molecular genetics, primarily funded by public grants including FWF and ERC.
Ownership category
akta.pro rank

Where Institute of Molecular Biotechnology is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
Austria
HQ region
Europe

Offices2 records

Markets served

Institute of Molecular Biotechnology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

  1. Academic Publishing and Book Sales: The Austrian Academy of Sciences Press (Verlag der Österreichischen Akademie der Wissenschaften) generates revenue through the sale of academic books, journals, and publications across disciplines including classical studies, archaeology, history, linguistics, musicology, and natural sciences. Publications are sold via an e-commerce storefront with pricing ranging from approximately €8 to €208 per item.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAcademic book and journal sales

Distribution channels3 records

Marketing channels6 records

Institute of Molecular Biotechnology product offering

Product offering

Core offering

IMBA is a non-profit molecular biology and biomedical research institute conducting advanced research in stem cell biology, organoid technology, molecular genetics, and 3D cell culture models, with particular prominence in brain organoid research. Its outputs include peer-reviewed scientific publications, trained researchers, and collaborative research with universities and research institutions across Europe.

Differentiator

Problem solved

Functional benefit

Products and services

  • Molecular biology and biomedical research services Fundamental and applied research in molecular biology, stem cell biology, organoid technology, molecular genetics, and 3D cell culture models, delivered to academic collaborators, universities, and research institutions.
  • Brain organoid research program Research program producing lab-grown human brain organoid models used by collaborators and academic partners to study neurodevelopmental conditions and test potential treatments.

Quantifiable outcome

  • Vienna Yearbook of Population Research achieved Q1 ranking in Scimago Journal-Ranking for the first time in 13 years

Companies that use Institute of Molecular Biotechnology

Customer profile

Segments1 record

Ideal customer profiles2 records

Institute of Molecular Biotechnology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Institute of Molecular Biotechnology partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • JSTORcoreTechnology or IntegrationThe ÖAW Press partners with JSTOR for the digital distribution and academic indexing of its publications, enabling broad discoverability and access for academic institutions worldwide.
  • ORCIDcoreTechnology or IntegrationORCID integration is supported and recommended for all authors publishing with the ÖAW Press, enabling unique researcher identification and attribution across publications.
  • CrossRefcoreTechnology or IntegrationCrossRef DOI services are used for all ÖAW Press publications, ensuring reliable citation linking and metadata standards.
  • Association of European University Presses (AEUP)coreGTM or Marketing PartnerThe ÖAW Press is a member of AEUP, a network of European university presses that promotes scholarly publishing and shares best practices across institutions.
  • Arbeitsgemeinschaft der UniversitätsverlagecoreStrategic or Co-development PartnerThe ÖAW Press participates in the Working Group of University Publishers (AG Universitätsverlage), coordinating with other German-speaking academic publishers on shared standards and practices.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Institute of Molecular Biotechnology competitors and assessment

Company assessment

Direct peers

  • European Molecular Biology Laboratory (EMBL): Intergovernmental research organization with sites across Europe conducting molecular biology and life science research; directly comparable as a publicly funded, multi-site European molecular biology research institute at similar scale and mission.
  • Max Planck Institute for Molecular Genetics: German publicly funded research institute focused on molecular genetics, genomics, and developmental biology; closely comparable mission, funding model, and scientific scope to IMBA within the same DACH-region academic ecosystem.
  • Francis Crick Institute: Large UK biomedical research institute conducting discovery research in molecular biology, stem cells, and genetics; directly comparable as a non-university, publicly funded biomedical research institute with similar headcount range and translational scope.
  • Wellcome Sanger Institute: UK-based genomic and molecular biology research institute; comparable in its focus on molecular genetics, cell biology, and large-scale research infrastructure funded primarily through philanthropic and public grants.
  • Whitehead Institute for Biomedical Research: MIT-affiliated non-profit biomedical research institute with similar headcount and focus on molecular biology, stem cells, and genetics; comparable as a small-to-mid-size, mission-driven research institute with strong publishing output.
  • Broad Institute of MIT and Harvard: US non-profit biomedical and genomic research organization; comparable in its mission-driven molecular biology and genomics research, though at substantially larger scale and with deeper industry partnership models.
  • CeMM Research Center for Molecular Medicine: Vienna-based molecular medicine research institute also operating under the Austrian Academy of Sciences; the closest geographic and institutional peer, conducting molecular-level biomedical research with similar funding structures and ÖAW affiliation.

Broad incumbents

  • Institut Pasteur: Historic French non-profit research foundation with broader scope spanning infectious disease, immunology, and molecular biology; comparable as a publicly chartered European research institution, though operating at larger scale and broader thematic range.
  • Karolinska Institutet: Sweden's leading medical university with substantial molecular biology and stem cell research programs; comparable as a publicly funded European institution conducting advanced biomedical research, though operating as a university rather than a standalone research institute.

Regional players

  • Helmholtz Centre for Infection Research: German publicly funded life sciences research institute within the Helmholtz Association; comparable in its DACH-region public funding model and molecular/cellular biology research portfolio, though more focused on infectious disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Institute of Molecular Biotechnology social profiles

Digital presence

Institute of Molecular Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Institute of Molecular Biotechnology leadership team

Management profile

Number of profiles

Institute of Molecular Biotechnology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Institute of Molecular Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute of Molecular Biotechnology

What does Institute of Molecular Biotechnology do?

IMBA is a non-profit molecular biology and biomedical research institute conducting advanced research in stem cell biology, organoid technology, molecular genetics, and 3D cell culture models, with particular prominence in brain organoid research. Its outputs include peer-reviewed scientific publications, trained researchers, and collaborative research with universities and research institutions across Europe.

Is Institute of Molecular Biotechnology a public or private company?

Institute of Molecular Biotechnology is a private company. It is classified as state government owned and is currently operating.

When was Institute of Molecular Biotechnology founded?

Institute of Molecular Biotechnology was founded in 2003. It employs 101 to 250 people.

Where is Institute of Molecular Biotechnology based?

Institute of Molecular Biotechnology is headquartered in Vienna, Austria, in the Europe region.

How does Institute of Molecular Biotechnology make money?

One revenue line is on record: academic Publishing and Book Sales.

Who are Institute of Molecular Biotechnology's main competitors?

Direct peers on record are European Molecular Biology Laboratory (EMBL), Max Planck Institute for Molecular Genetics, Francis Crick Institute, Wellcome Sanger Institute, Whitehead Institute for Biomedical Research, Broad Institute of MIT and Harvard and CeMM Research Center for Molecular Medicine. Broad incumbents are Institut Pasteur and Karolinska Institutet. Helmholtz Centre for Infection Research is listed as a regional player.

Does Institute of Molecular Biotechnology have an API?

No public API is recorded for Institute of Molecular Biotechnology.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OeawDaan de Groot to start research group at IMBADaan de Groot is establishing a new research group at the Institute of Molecular Biotechnology (IMBA) to investigate the principles governing cell-fate decisions. The lab will utilize computational modeling and single-cell data analysis to map gene regulatory logic and improve organoid models for studying developmental diseases. This initiative aims to uncover how cells make reliable decisions in noisy environments through theoretical exploration and collaborative projects.PR NewswireIMBA - Institut für Molekulare Biotechnologie GmbH: Growing Brain Cancer in a DishResearchers at IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences have developed, for the first time, neoplastic cerebral organoids that model brain tumor formation, allowing them to replicate glioblastoma onset in a laboratory dish and observe cancer development from early stages. The study, published in Nature Methods, demonstrates that these organoids can be used to test gene mutations from cancer genome projects and evaluate drug efficacy, showing that EGFR inhibitors like Afatinib and Erlotinib significantly reduced tumor cells in certain mutation combinations. The researchers aim to establish clinical partnerships to translate these laboratory findings into practical medical applications for brain cancer treatment.PR NewswireIMBA - Institut für Molekulare Biotechnologie GmbH: Growing Brain Cancer in a DishResearchers at IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences have developed neoplastic cerebral organoids that for the first time allow brain cancer onset to be replicated and studied in a laboratory dish. The study, published in Nature Methods, demonstrates that these organoids can faithfully reproduce human brain characteristics and tumor formation, enabling scientists to test gene mutations and screen potential therapies. The researchers found that drugs like Afatinib and Erlotinib significantly reduced tumor cell numbers in certain mutation combinations, showing promise for advancing glioblastoma treatment research.